01 9Benepali
02 4Brenzys
03 21Enbrel
04 1Enbrel (Outside the U.S. and Canada)
05 2Enbrel (Outside The U.S. And Canada)
06 2Enbrel (Outside the U.S. and Canada)
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 291
2018 Revenue in Millions : 334
Growth (%) : -13
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 4,996
2019 Revenue in Millions : 5,226
Growth (%) : -4
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 482
2019 Revenue in Millions : 486
Growth (%) : -1
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 1,699
2018 Revenue in Millions : 2,112
Growth (%) : -20
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 1,350
2019 Revenue in Millions : 1,699
Growth (%) : -21
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 4,465
2020 Revenue in Millions : 4,996
Growth (%) : -11
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 498
2020 Revenue in Millions : 482
Growth (%) : 3
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 1,185
2020 Revenue in Millions : 1,350
Growth (%) : -12
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 63
2020 Revenue in Millions : 74
Growth (%) : -15
Main Therapeutic Indication : Dermatology
Currency : USD
2022 Revenue in Millions : 75
2021 Revenue in Millions : 63
Growth (%) : 19
